HanchorBio Announces Oral Presentation of HCB101 at the ESMO Immuno-Oncology Congress 2025
International debut underscores emerging role for macrophage checkpoint therapy in gastric cancer, triple-negative breast cancer, and other hard-to-treat solid tumors
HanchorBio Inc. (TPEx: 7827), a global clinical-stage biotechnology company advancing next-generation immunotherapies for oncology and autoimmune diseases, today announced that new clinical data from its flagship macrophage-checkpoint program, HCB101, has been selected for a mini oral presentation at the ESMO Immuno-Oncology Congress 2025 in London, United Kingdom. Only 26 abstracts were chosen for mini-oral presentation this year, marking a major milestone for HanchorBio as it delivers its first-ever oral presentation of clinical data at an international oncology congress, following its prior preclinical oral presentation of HCB101 at SITC 2022.
The ESMO Immuno-Oncology Congress is Europe’s premier meeting dedicated exclusively to immuno-oncology science, distinct from the broader ESMO Annual Congress. While the annual ESMO meeting spans all oncology disciplines, ESMO-IO focuses on immune mechanisms, translational innovation, and next-generation therapeutic strategies across innate and adaptive immunity.
Presentation Details:
- Abstract ID: 242MO
- Title: HCB101, a Differentiated SIRPα Fusion Protein, Demonstrates Favorable Safety and Early Antitumor Activity Across Solid Tumors and Lymphoma
- First Author: Dr. Fangling Ning, Affiliated Hospital of Binzhou Medical University
- Date / Time: 11 December 2025 / 11:45 – 12:45 GMT
- Location: Whittle Room, Queen Elizabeth II Centre, London
- Presenter: Alvin Luk, PhD, MBA, CCRA – President & CMO (Group) and CEO (U.S.A.), TIME100 Health 2025 Honoree
漢康生技HCB101獲選2025年ESMO免疫腫瘤學大會口頭報告
展現巨噬細胞檢查點療法於胃癌、三陰性乳癌等難治性實體瘤中的新興治療潛力
致力於開發下一代腫瘤及自身免疫疾病免疫療法的全球臨床階段生物技術公司漢康生技（TPEx: 7827）今日宣佈，其主力創新融合蛋白生物藥HCB101的臨床數據，已被遴選為2025年歐洲腫瘤學會 (ESMO, European Society For Medical Oncology) 免疫腫瘤學大會 (Immuno-Oncology Congress) 的小型口頭簡報，並於英國倫敦舉行。今年僅有26篇摘要獲此報告資格，這意味著漢康生技首次在國際頂級腫瘤學術會議上進行臨床資料口頭報告，是其繼2022年在免疫治療學會大會(SITC, Society for Immunotherapy of Cancer) 上報告HCB101臨床前資料後的又一重大里程碑。
ESMO免疫腫瘤學大會是歐洲專注於免疫腫瘤科學的首要盛會，與涵蓋更廣泛腫瘤領域的 ESMO 年度大會不同，ESMO 年會聚焦於全方位的腫瘤學研究與臨床進展，而免疫腫瘤學大會則專注於免疫機制、轉譯醫學創新，以及涵蓋先天與適應性免疫的下一代治療策略。
大會資訊：
- 摘要編號：242MO
- 標題：HCB101，一款差異化的SIRPα融合蛋白，在實體瘤和淋巴瘤中顯示出良好的安全性和早期抗腫瘤活性
- 第一作者：甯方玲博士，濱州醫學院附屬醫院
- 時間：2025年12月11日，11:45 – 12:45（GMT）
- 地點：倫敦伊莉莎白二世女王中心 (Whittle Room)
- 報告人：陸英明博士 (Alvin Luk) – 集團總裁兼醫療長，2025年《時代》週刊健康領域百大影響力人物